Who are Kyntra Bio, Inc.'s main suppliers?

Kyntra Bio, Inc. (KYNB) key suppliers include: NOVAQUEST, AstraZeneca PLC, AstraZeneca PLC. View the full supplier network at chainsifter.com/chain/KYNB.

Who are Kyntra Bio, Inc.'s major customers?

Kyntra Bio, Inc. (KYNB) key customers include: FALIKANG, AstraZeneca PLC, AstraZeneca PLC, ASTELLAS-PHARMA-INC, ASTRAZENECA-TREASURY-LIMITED and 6 more. View the full customer network at chainsifter.com/chain/KYNB.

What sector is Kyntra Bio, Inc. in?

Kyntra Bio, Inc. (KYNB) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Kyntra Bio, Inc. Supplier List (KYNB): 3 Verified Suppliers

3Suppliers

11Customers

2Debt Items

20Related Chains

Source-Backed Evidence Depth

Kyntra Bio, Inc. (KYNB) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

17Total relationships

2Distinct source URLs

7High confidence

0.742Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Kyntra Bio, Inc. Suppliers

Ticker	Name	Confidence	Evidence
NOVAQUEST	NOVAQUEST	92%	Company entered into a Revenue Interest Financing Agreement (the “RIFA”) with an affiliate of NovaQuest Capital Management ("NovaQuest"), pursuant to which the Company granted NovaQuest 22.5 % of its…
AZN	AstraZeneca PLC	72%	straZeneca for the development and commercialization of roxadustat. For the years ended December 31, 2024 and 2023, our revenue for continuing operations was substantially related to our collaboratio…
AZN	AstraZeneca PLC	72%	Reciprocal relationship from AZN graph: Reciprocal relationship from KYNB graph: Reciprocal relationship from AZN graph: Reciprocal relationship from KYNB graph: straZeneca for the development and co…

Kyntra Bio, Inc. Customers

Ticker	Name	Confidence	Evidence
FALIKANG	FALIKANG	90%	Our proportionate share of the reported profits or losses of Falikang, was included in the discontinued operations in the condensed consolidated statement of operations. See Note 2, Discontinued Oper…
AZN	AstraZeneca PLC	85%	Reciprocal relationship from AZN graph: Reciprocal relationship from KYNB graph: In July 2013, the Company (through its subsidiaries affiliated with China) entered into a collaboration agreement with…
AZN	AstraZeneca PLC	85%	In July 2013, the Company (through its subsidiaries affiliated with China) entered into a collaboration agreement with AstraZeneca for roxadustat for the treatment of anemia in China ("AstraZeneca Ch…
ASTELLAS-PHARMA-INC	ASTELLAS-PHARMA-INC	62%	advantages of the product candidate over alternative treatments, including any similar generic treatments; • the inclusion or exclusion of the product candidate from treatment guidelines established …
ASTRAZENECA-TREASURY-LIMITED	ASTRAZENECA-TREASURY-LIMITED	62%	advantages of the product candidate over alternative treatments, including any similar generic treatments; • the inclusion or exclusion of the product candidate from treatment guidelines established …
ASTS	AST SpaceMobile, Inc.	62%	Reciprocal relationship from ASTS graph: Reciprocal relationship from KYNB graph: Reciprocal relationship from ASTS graph: Reciprocal relationship from KYNB graph: Reciprocal relationship from ASTS g…
BAC	Bank of America Corporation	62%	Reciprocal relationship from BAC graph: Reciprocal relationship from KYNB graph: Reciprocal relationship from BAC graph: Reciprocal relationship from KYNB graph: Reciprocal relationship from BAC grap…
BOFA-SECURITIES-INC	BOFA-SECURITIES-INC	62%	n, or 1,529%, for the three months ended March 31, 2026, compared to the same period a year ago, primarily due to the cost associated with the intermediates drug product revenue of $3.3 million and t…
CAPITAL-RESOURCES	CAPITAL-RESOURCES	62%	nities for this late-stage program. We are now finalizing the Phase 3 trial protocol for roxadustat for the treatment of anemia in patients with lower-risk MDS and high transfusion burden after recei…
FIBROGEN-CHINA-ANEMIA-HOLDINGS-LTD	FIBROGEN-CHINA-ANEMIA-HOLDINGS-LTD	62%	n, or 1,529%, for the three months ended March 31, 2026, compared to the same period a year ago, primarily due to the cost associated with the intermediates drug product revenue of $3.3 million and t…
FORTIS-THERAPEUTICS-INC	FORTIS-THERAPEUTICS-INC	62%	advantages of the product candidate over alternative treatments, including any similar generic treatments; • the inclusion or exclusion of the product candidate from treatment guidelines established …

Kyntra Bio, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
KYNB-DEBT	Debt stack $75.0M	90%	Market cache reports total debt of $75.0M.
KYNB-DEBT-10597	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2015-12-31.

Kyntra Bio, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Kyntra Bio, Inc..

Kyntra Bio, Inc. Ownership

Holder	Name	Confidence	Evidence
KYNB-OWNER-ARMISTICE-CAPITAL-LLC	ARMISTICE CAPITAL, LLC	90%	13F overlay lists ARMISTICE CAPITAL, LLC as top holder; 34 tracked holders.

Kyntra Bio, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
SLN	Silence Therapeutics plc	100.00	2
ARGX	argenx SE	100.00	2
BAC	Bank of America Corporation	100.00	1	['customer']
TNXP	Tonix Pharmaceuticals Holding Corp.	100.00	2
MGNX	MacroGenics, Inc.	100.00	2
APRE	Aprea Therapeutics, Inc.	100.00	2
ALNY	Alnylam Pharmaceuticals, Inc.	100.00	2
CPMV	Mosaic ImmunoEngineering, Inc.	100.00	2
DRTS	Alpha Tau Medical Ltd.	100.00	2
IDYA	IDEAYA Biosciences, Inc.	100.00	2
CHRS	Coherus Oncology, Inc.	100.00	2
OLMA	Olema Pharmaceuticals, Inc.	100.00	2
CCCC	C4 Therapeutics, Inc.	100.00	2
ALLO	Allogene Therapeutics, Inc.	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
CRBP	Corbus Pharmaceuticals Holdings, Inc.	100.00	2
CTNM	Contineum Therapeutics, Inc.	100.00	2
BCAX	Bicara Therapeutics Inc.	100.00	2
DEO	Diageo plc	100.00	2
SNYNF	Sanofi	100.00	2

Kyntra Bio, Inc. Supply Chain